Drug Trial Radar · NCT01377844
Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jul 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
288
Actual
Start
Dec 2011
Primary completion
Nov 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- TheracosIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy of EGT0001442 in lowering glycosylated Hemoglobin (HbA1c, A laboratory test to diagnose three months average of blood sugar)levels at 24th week from baseline, when compared to placebo group(no diabetic medication given). The secondary aim of the study is to evaluate the efficacy of EGT0001442 in lowering fasting blood glucose at the weeks 2 and 24 and comparing the results with placebo group. This study assess the efficacy of EGT0001442 based on the proportion of subjects who reach the American Diabetes Association (ADA) target of HbA1c of \< 7% in EGT0001442 group and comparison with placebo. The study also evaluates the effect of EGT0001442 on systolic, diastolic pressures, body weight and compare with the respective placebo groups.This study also assess the change from baseline in HbA1c overtime, from week 1 to week 96. Finally, to assess the safety of EGT0001442 in the Type 2 Diabetic patients (adult/maturity onset).
Conditions
- Diabetes Mellitus
Interventions
EGT0001442Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1c at 24 WeeksTime frame: Baseline and Week 24
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Site 5
Buena Park, California
Site 4
Los Angeles, California
Site 3
Santa Ana, California
Site 1
Hialeah, Florida
Site 9
Berlin, New Jersey
Site 7
Cary, North Carolina
Site 6
Marion, Ohio
Site 8
Munroe Falls, Ohio
Site 2
Portland, Oregon
Site 11
North Richland Hills, Texas
Site 7
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.